Skip to content

Insider · CIK 0001706847

Mark A. Velleca

ceopresidentofficerdirector

Files at BDTX (Black Diamond Therapeutics, Inc.). First filing -, latest -.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold

Signals

This insider’s open-market buys and sells, scored.

No scored open-market trades yet.

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Jan 21, 2026BDTX
Black Diamond Therapeutics, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+600,000$0.00$0600,000Jan 23, 2026
Jan 30, 2025BDTX
Black Diamond Therapeutics, Inc.
AGrant or award
Common Stock
+75,000$0.00$0121,522Jan 31, 2025
Jan 30, 2025BDTX
Black Diamond Therapeutics, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+500,000$0.00$0500,000Jan 31, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Mark A. Velleca: insider trades and track record | InsiderTell